Results 21 to 30 of about 349 (107)

The Evolution of Medications for Obesity Management. [PDF]

JGH Open
ABSTRACT This narrative review provides an overview of progress in the development of obesity medications, including a synthesis of data describing the efficacy and safety of currently available agents and emerging therapeutic options. Historically, many obesity medications have been withdrawn from the market due to safety concerns.
Gill J, Sumithran P.
europepmc   +2 more sources

What is the pipeline for future medications for obesity?

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and ...
Eka Melson (12122895), Uzma Ashraf (17971937), Melanie J. Davies (171604)   +2 more
core   +9 more sources

AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY [PDF]

Journal of IMAB
Amylin is a peptide hormone co-synthesized with insulin in pancreatic beta cells at a ratio of 1:100. Notably, amylin has a pronounced tendency to form toxic amyloid fibrils, a characteristic relevant to its pathological role.
Nikolinka Koleva, Boris Dinkov, Galya Stavreva   +2 more
doaj   +1 more source

Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare. [PDF]

World J Cardiol
The ground-breaking development of the incretin agonists by manipulation of the incretin system, including the gut hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), as well as the pancreatic hormone glucagon,
Bhat S, Fernandez CJ, Lakshmi V, Pappachan JM.   +3 more
europepmc   +3 more sources

تأثیر آگونیست‌های گیرنده‌ی GLP-1 و درمان‌های غیرتزریقی بر کنترل قند خون و مدیریت وزن در بیماران مبتلا به دیابت نوع ۲ [PDF]

مجله دانشکده پزشکی اصفهان
مقدمه: دیابت نوع ۲، یکی از بیماری‌های مزمن شایع است که بزرگسالان را در سراسر جهان تحت تأثیر قرار داده است. در سال‌های اخیر، پیشرفت‌های قابل توجهی در درمان این بیماری حاصل شده که از جمله آن‌ها می‌توان به معرفی آگونیست‌های گیرنده‌ی پپتید شبه گلوکاگون-۱ ...
مریم شریفی, جلال مولودی, صادق مظاهری-تهرانی, زینب جمشیدی محمود آبادی, نسیم علی حلوایی   +4 more
doaj   +1 more source

Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis

VIEW, EarlyView.
In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian, Keke Zhang, Wenwen He, Yan Ke, Yi Lu, Xiangjia Zhu   +5 more
wiley   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Tirzepatide vs. Cagrilintide/Semaglutide: A New Frontier in Pharmacological Management of Obesity

Journal of Education, Health and Sport
Obesity is a chronic, multifactorial disease with escalating global prevalence, associated with profound metabolic, cardiovascular, and oncological comorbidities.
Marcelina Rybińska, Hanna Rzepka, Paweł Stępowski, Mateusz Tajster   +3 more
doaj   +1 more source

Therapeutic access points: The roles of circumventricular organs in drug delivery and metabolic regulation

British Journal of Pharmacology, EarlyView.
The current obesity drug landscape, dominated by GLP‐1 receptor agonists and emerging multi‐agonist therapies, has reinforced that long‐term weight loss is achieved in large part through central mechanisms that suppress appetite and reshape energy balance.
Ines Martinez‐Corral, Nicholas Monaco, Daniel I. Brierley, Monica Imbernon   +3 more
wiley   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source